Conventional grade 1 chondrosarcoma: a challenging diagnosis with important implications on therapy and prognosis

Cozma, Gabriel; Sima, Laurentiu; Cloşca, Raluca Maria; Baderca, Flavia; Horhat, Ioana Delia; Balica, Nicolae Constantin; Tischer, Alina Andreea; Moţ, Ion Cristian; Malița, Daniel; Marin, A; Sarău, Cristian Andrei

doi:10.47162/rjme.62.2.30

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prospective cohort studies are particularly recommended to validate the prognostic significance of biomarkers like BMI, lymphocyte counts, and inflammatory indices such as NLR, PLR, SII, and the NHL score. Moreover, in-depth genetic and molecular studies underlying E-Cadherin dysregulation in these cancers, particularly considering the loss of E-Cadherin in various highly malignant and dedifferentiated cancers such as Chondrosarcoma and small cell carcinomas of the urinary bladder, as well as for reduced E-Cadherin expression like invasive lobular breast cancer and colorectal cancer [ 33 , 34 ], could elucidate the pathways through which these biomarkers interact with CRC progression. Another promising area involves exploring the impact of tumor stage and location on biomarker efficacy, potentially tailoring prognostic tools to enhance precision in clinical settings.…”

Section: Discussionmentioning

confidence: 99%

Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies

Popovici,

Stanisav,

Sima

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and objectives: Colorectal cancer is a major global health concern, with a significant increase in morbidity and mortality rates associated with metastatic stages. This study investigates the prognostic significance of various clinical and laboratory parameters in patients with metastatic CRC. Materials and Methods: A retrospective cohort of 188 CRC patients with hepatic metastasis from the OncoHelp Association in Timisoara was analyzed from January 2016 to March 2023. Data on demographics, clinical characteristics, and biomarkers, such as lymphocyte counts, as well as various inflammation indices, were examined. Statistical analyses included univariate and multivariate logistic regression, Kaplan-Meier survival analysis, and ROC curve assessments. Results: Our findings indicate significant associations between survival outcomes and several biomarkers. Higher BMI and lymphocyte counts were linked with better survival rates, while higher values of Neutrophil-Hemoglobin-Lymphocyte (NHL) score, Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR), and Systemic Immune-Inflammation Index (SII) were predictors of poorer outcomes. Notably, the presence of hepatic metastasis at diagnosis was a critical factor, significantly reducing overall survival. Conclusions: The study has expanded the current understanding of prognostic factors in CRC, advocating for a multi-dimensional approach to prognostic evaluations. This approach should consider not only the traditional metrics such as tumor stage and histological grading but also incorporate a broader spectrum of biomarkers. Future studies should aim to validate these findings and explore the integration of these biomarkers into routine clinical practice, enhancing the precision of prognostic assessments and ultimately guiding more personalized treatment strategies for CRC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies

Popovici,

Stanisav,

Sima

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Chondrosarcoma relapses and metastases often, thus it is important to identify biomarkers that determine the best clinical approach. Diagnosing chondrosarcomas can be challenging due to its rather common symptoms, low incidence, and grading system [ 17 ]. As such, making a correct diagnosis is a key factor for the overall treatment of the tumor.…”

Section: Introductionmentioning

confidence: 99%

Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions

Gilbert

Tudor

Montanari

et al. 2023

Cancers

View full text Add to dashboard Cite

Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can be explained by the particular composition of the tumor, which develops within a dense cartilaginous matrix, producing a resistant area where the oxygen tension is very low. This microenvironment forces the cells to adapt and dedifferentiate into cancer stem cells, which are described to be more resistant to conventional treatments. One of the main avenues considered to treat this type of tumor is hadrontherapy, in particular for its ballistic properties but also its greater biological effectiveness against tumor cells. In this review, we describe the different forms of chondrosarcoma resistance and how hadrontherapy, combined with other treatments involving targeted inhibitors, could help to better treat high-grade chondrosarcoma.

show abstract

Condrosarcoma central de escápula izquierda: reporte de caso

Tamayo-Gómez,

Cariño-Cepeda,

Loredo-Loyola

et al. 2024

Ortho-Tips

View full text Add to dashboard Cite

Conventional grade 1 chondrosarcoma: a challenging diagnosis with important implications on therapy and prognosis

Cited by 3 publications

References 29 publications

Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies

Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies

Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions

Condrosarcoma central de escápula izquierda: reporte de caso

Contact Info

Product

Resources

About